What happened in the stock market today

As the Brexit waiting game continues, company news today included the shock departure of a FTSE 100 chief executive.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 and the pound started this morning modestly positive and maintained it for much of the day. The Brexit waiting game goes on. Commons Speaker John Bercow refused the government’s call to hold another vote on the Prime Minister’s Brexit deal today.

Blue-chip boss departure

In today’s company news, the healthcare sector was prominent. Pharma giants AstraZeneca and GlaxoSmithKline both had updates, albeit with no big impact on their share prices.

AZN announced its Farxiga treatment has been approved in the US to reduce the risk of hospitalisation for heart failure in patients with type-2 diabetes. GSK revealed it’s agreed to divest its rabies and tick-borne encephalitis vaccines to Danish firm Bavarian Nordic. This for an upfront payment of €301m (£259m), with milestone payments taking the total consideration up to €955m (£822m).

Meanwhile, Circassia Pharmaceuticals announced the US launch of Duaklir for the treatment of chronic obstructive pulmonary disease. The company described the launch as “a major strategic milestone.” The market shrugged, and sent the small-cap firm’s shares a few percent lower.

Returning to the FTSE 100, healthcare firm Smith & Nephew saw a big move in its shares. Down. As much as 10% at one point. This followed a shock announcement that chief executive Namal Nawana is stepping down after less than 18 months in the job.

The company said Nawana will leave on 31 October, “by mutual agreement … to pursue other opportunities outside of the UK.” Behind this are reports the company couldn’t, or wouldn’t, meet his demands for higher pay, in line with the bosses of US medical device-makers.

Other big FTSE 100 fallers

Just Eat and Prudential spent most of the day vying with Smith & Nephew for the bottom slot on the FTSE 100 fallers board. Just Eat’s drop follows the release of its Q3 results in which key metrics were below City expectations. While the company reconfirmed its full-year revenue and earnings guidance, analysts expect the consensus to move down to the lower end of the range.

My Foolish colleague Alan Oscroft doesn’t downplay the potential of the food ordering platform and delivery business. However, he has some wise words on early movers with shares on super high valuations.

Insurer Prudential’s fall was triggered by today’s formal demerger of its M&G UK asset management business. An investor who owned 1,000 Prudential shares on Friday now also owns 1,000 shares in the separate M&G company. After reviewing today’s developments, fellow Fool Roland Head concluded he’d be happy to own either – or both stocks.

Mid-cap movers

In the FTSE 250, Capital & Counties Properties, the owner of Covent Garden and Earls Court, was prominent among the risers. This came after confirmation a consortium led by Candy Ventures is in the early stages of considering a possible cash offer for the company.

At the other end of the mid-cap movers board, troubled technology firm Micro Focus International was rooted to the bottom for most of the day. A Bloomberg report that Canadian group OpenText was weighing a bid for the company was scotched by OpenText in a statement this morning.

Small-cap shooting star

Finally, the biggest riser on the London market was AIM-listed Watchstone (formerly Quindell). The company’s long-running battle over £50m with Australian firm Slater & Gordon has been settled. Watchstone’s getting £39m from the pot and S&G £11m.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca, GlaxoSmithKline, Micro Focus, and Prudential. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

2 top growth stocks to consider for an ISA in April

The UK market is home to some fantastic under-the-radar growth stocks trading at very reasonable valuations. Here are two of…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Could thinking like Warren Buffett help create a market-beating ISA?

Christopher Ruane zooms in on some aspects of Warren Buffett's investing approach he thinks could help an ambitious ISA investor…

Read more »

British pound data
Investing Articles

£10,000 invested in a FTSE 100 index tracker at the start of March is now worth…

Anyone who invested money in a FTSE 100 index tracker at the start of the month may wish to look…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

Should investors consider Rolls-Royce shares as war rocks global markets?

Investors who thought Rolls-Royce shares had grown too expensive might have second thoughts as Iran turmoil rattles the FTSE 100,…

Read more »

Young black woman walking in Central London for shopping
Investing Articles

Some lucky ISA investors could pick up £2,000 for free in the next month. Here’s how

The UK government is handing out free money to some ISA investors to help them save for retirement. Here’s a…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Is this the best time to buy dividend shares since Covid-19?

A volatile stock market gives investors a chance to buy shares with unusually high dividend yields. Stephen Wright highlights one…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Are we staring at a once-in-a-decade chance to buy this beaten-down UK growth stock?

Investors couldn't get enough of this FTSE 100 growth stock, but the last 10 years have been pretty frustrating. Could…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

What I look for when searching for shares to buy

There’s a lot that goes into finding shares to buy. Ultimately though, it comes down to two things: numbers that…

Read more »